Inhibition effect of SARS-CoV-2 and survival cell ratio by concentration in experimental group
Substance | Concentration (µM) |
Inhibition-normalized infection ratio | Cell number to mock (%) | IC50 | CC50 | SI | |||
---|---|---|---|---|---|---|---|---|---|
1st | 2nd | 1st | 2nd | ||||||
PPAR-γ agonist-1 | 50.00 | 0.07 | -0.36 | 101.20 | 101.37 | >50 | >50 | 1.0 | |
25.00 | -1.42 | 1.80 | 101.18 | 101.57 | |||||
12.50 | -1.27 | 2.14 | 102.75 | 102.43 | |||||
6.25 | 0.33 | 1.29 | 104.11 | 99.55 | |||||
3.13 | 1.85 | 0.29 | 101.00 | 98.76 | |||||
1.56 | 1.09 | 0.41 | 103.81 | 98.93 | |||||
0.78 | 0.02 | -0.22 | 103.12 | 96.27 | |||||
0.39 | 1.16 | 1.26 | 100.88 | 101.20 | |||||
0.20 | 1.03 | -0.52 | 100.12 | 101.42 | |||||
0.10 | 0.82 | -0.93 | 102.26 | 100.86 | |||||
PPAR-γ agonist-2 | 50.00 | 3.19 | 13.50 | 102.75 | 108.47 | >50 | >50 | 1.0 | |
25.00 | 1.57 | 3.98 | 106.69 | 104.77 | |||||
12.50 | 3.00 | 4.83 | 107.19 | 108.02 | |||||
6.25 | 0.56 | 3.59 | 106.33 | 109.06 | |||||
3.13 | 0.86 | 5.18 | 105.61 | 105.93 | |||||
1.56 | 2.34 | 1.92 | 106.87 | 107.80 | |||||
0.78 | 4.01 | 4.17 | 109.95 | 107.04 | |||||
0.39 | 1.15 | 1.46 | 106.69 | 105.91 | |||||
0.20 | 2.76 | 0.50 | 105.49 | 107.14 |
PPAR-γ, peroxisome proliferator-activated receptors-gamma; IC, inhibitory concentration; CC, cytotoxic concentration; SI, selectivity index.